<?xml version="1.0" encoding="UTF-8"?>
<p>Physicians need to be aware that immunoglobulins are not specifically effective against SARS-CoV-2 because of a lack of specific antibodies within the product, but can help in preventing additional infections. Bacterial secondary infection can complicate viral infections, a situation well known in influenza, and emerging in COVID-19.
 <sup>
  <xref rid="R120" ref-type="bibr">120</xref>,
  <xref rid="R121" ref-type="bibr">121</xref>
 </sup> Immunoglobulin replacement therapy reduces the risk of major infection in patients with CLL and low serum IgG.
 <sup>
  <xref rid="R122" ref-type="bibr">122</xref>
 </sup> Subcutaneous formulations are non-inferior to intravenous formulations with the advantage of being self-administered by patients at home after a short training.
 <sup>
  <xref rid="R123" ref-type="bibr">123</xref>
 </sup> Given the higher risk of thromboembolic events with COVID-19, we recommend assessment of risks vs. benefits in each patient and close monitoring for thromboembolic symptoms.
</p>
